Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Leukemia, Myeloid, Acute 2Sinonasal undifferentiated carcinoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Esthesioneuroblastoma, Olfactory 1Chondrosarcoma 1

Interventions

Erlotinib Hydrochloride 3Bevacizumab 3Radiotherapy 2Filgrastim 2Cetuximab 2sargramostim 1oncogene protein E7, Human papillomavirus type 16 1entinostat 1enasidenib 1aldesleukin 1Vorinostat 1Tomography, X-Ray Computed 1Thiotepa 1Ritonavir 1Radionuclide Imaging 1Radiation 1Positron-Emission Tomography 1Peripheral Blood Stem Cell Transplantation 1Magnetic Resonance Spectroscopy 1Irinotecan 1Indinavir 1Ibuprofen 1Hydroxyurea 1Granulocyte Colony-Stimulating Factor 1Gefitinib 1Fluorouracil 1Etoposide 1Epirubicin 1Electrocardiography 1E6 protein, Human papillomavirus type 16 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Esthesioneuroblastoma, Olfactory × enasidenib × Clear all
NCT06176989 2026-06-03

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
40 enrolled
CNSSarcoma

Sinonasal undifferentiated carcinoma, Chondrosarcoma, Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡